Scarica l'app Stockscreener
1.17
16.43%
-0.23
Dopo l'orario di chiusura:
1.18
0.01
+0.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Biovie Inc Borsa (BIVI) Ultime notizie
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - New Castle News
BioVie Phase 2b Parkinson’s Trial Meets Primary Endpoint - Minichart
BioVie Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - marketscreener.com
These stocks have an unusual volume in today's session - ChartMill
BioVie Q4 Results: EPS loss narrows 51% YoY to $(0.70) - scanx.trade
BIVI Stock Jumps As SUNRISE-PD Data Fuels Parkinson’s Hopes - timothysykes.com
BIOVIE INC. FY 2026: Net loss $22.1M — 10-K Summary - TradingView
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
BIVI Stock Jumps As SUNRISE-PD Data Fire Up Parkinson’s Hopes - StocksToTrade
BIVI Stock Jumps As SUNRISE-PD Data Ignites Parkinson’s Hopes - timothysykes.com
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why BioVie (BIVI) Stock Is Up Today - Quiver Quantitative
BioVie Inc. Revenue Breakdown – NASDAQ:BIVIW - TradingView
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
New to The Street NASDAQ MARKETSITE - ACCESS Newswire
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results - newswire.com
Biovie Stock Price Forecast. Should You Buy BIVI? - StockInvest.us
Morgan Stanley (BIVI) discloses 896,822 BioVie shares, an 11.9% stake - Stock Titan
Morgan Stanley (BIVI) discloses 8.0% beneficial stake in BioVie Class A shares - Stock Titan
BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease - Bitget
BioVie Inc (BIVI) Stock News Today - TradingKey
Parkinson's drug developers are betting big on inflammation - Proactive financial news
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results - finance.yahoo.com
BioVie stock sinks on Phase IIb Parkinson’s trial data - Yahoo Finance
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease - markets.businessinsider.com
BioVieBezisterim Shows Statistically Signi - Moomoo
BioVie reports positive phase 2 trial results for Parkinson’s drug By Investing.com - Investing.com South Africa
BioVie shares halve on murky Parkinson’s disease readout - BioSpace
BioVie reports positive phase 2 trial results for Parkinson’s drug - Investing.com
BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program - Fierce Biotech
BIVI Stock Slides As New Equity Offering Looms Over Traders - StocksToTrade
BioVie Announces Positive Phase 2 Parkinson’s Trial Results - TipRanks
Form 8K Biovie Inc For: 6 August By Investing.com - Investing.com Canada
BioVie reports positive Phase 2 SUNRISE-PD topline results for bezisterim showing clinical and biomarker gains - TradingView
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim - Proactive financial news
BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programs - Bitget
BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial - Yahoo Finance
BioVie Shareholder Notice - TMX Newsfile
BioVie Ongoing Deadline Alert - TMX Newsfile
BioVie Inc. (BIVI) Climbs 6.29% to $1.52 as Momentum Builds Toward $1.60 ResistanceDaily Profile - dars.gov.et
[S-1/A] BIOVIE INC. Amends IPO Registration Statement - Stock Titan
BioVie Inc (BIVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioVie Inc (BIVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioVie Inc (BIVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioVie Inc (BIVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIVI|BioVie Inc|Price:1.400|Chg%:+0.030 - TradingKey
BIVI|BioVie Inc|Price:1.370| - TradingKey
BioVie Inc (BIVI) Earnings Date & Reports & Earnings News - TradingKey
BioVie Inc (BIVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
BioVie Inc (BIVI) Income Statement - TradingKey
BioVie Inc (BIVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioVie Inc (BIVI) Balance Sheet - TradingKey
BioVie Inc. (BIVI) Q2 2026 Earnings: Narrower-Than-Expected Loss as Biotech Advances Clinical PipelineRevenue Miss Report - dars.gov.et
BioVie Inc. Revenue Breakdown – NASDAQ:BIVI - TradingView
BIVI|BioVie Inc|Price:1.370|Chg%:-0.070 - TradingKey
BioVie Inc. (BIVI) Surges 3.88% as Stock Approaches Key ResistanceSmart Money Flow Stocks - dars.gov.et
BioVie Warrants (BIVIW) Hold Steady at $0.53 Amid Tight Trading RangeStrangle Setup - dars.gov.et
12 Health Care Stocks Moving In Monday's Pre-Market SessionAdvanced Biomed (NASDAQ:ADVB), Barinthus Bi - Benzinga
Daily Brief Health Care: JPJ (TCM) Limited(TCM), Abeona Therapeutics , Mani Inc, BioVie , Propanc Biopharma, Tivic Health Systems Inc and more - Smartkarma
IPO Databook: Biovie (BIVI US)Jul 2026 - Smartkarma
BioVie Files for a Stock Offering - Moomoo
[S-1] BIOVIE INC. Files IPO Registration Statement - Stock Titan
Form S-1 Biovie Inc For: 17 July By Investing.com - Investing.com UK
BIVIW SEC FilingsBiovie Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enterprise value to EBIT forward of BioVie Inc. – NASDAQ:BIVIW - TradingView
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):